The last 17 months has certainly brought on a lot of change, some planned and some not planned. Below are some of the major topics that our U.S. life and health clients have been focused on recently – and question how best to move forward.
It seems in 2021 that every couple of months I learn about a software solution, new process, or new service that innovates, enhances, and accelerates life insurance underwriting.
As part of an ongoing series in On the Risk, RGA's Taylor Pickett, an actuary, and Catie Muccigrosso, an underwriter, examine the relationship between their professions and underscore the crucial role underwriters play in the development and implementation of predictive tools and accurate pricing.
Simply stated, the law of large numbers in probability and statistics states that as a sample size grows, its mean gets closer to the average of the entire population.
Smokeless tobacco has been evolving over the past 55 years and now, with various forms of e-cigarettes and additives available, this once ‘safer’ recreational activity is showing implications on brain, lung, and cardiovascular function.
Aducanumab (Aduhelm), a new drug designed to treat Alzheimer's disease was approved by the FDA on June 7, 2021. RGA's Dr. Dave Rengachary discusses what this means for insurance, as well as the controversies around it.
Driven by the need to slow or stop the spread of COVID-19, accelerated underwriting may save lives while increasing sales of life insurance.
How will the COVID-19 pandemic impact life and health insurance distribution and sales in the long term? Peter Rodes and Eva Goldstein of RGAX, the transformation engine of RGA, discuss the key drivers of insurance's accelerated convergence.
Monty Forman, ALHC, FALU, FLMI Director of Underwriting Research, hosts the underwriting webinar: The Thick and Thin of Melanoma. Dr. Anuj Gupta, Senior UW Research Consultant, shares his insight and the following points:
 |
 |
 |
 |
 |
 |